Cytotoxic APIs Lonza to Expand Cytotoxic Manufacturing to Serve Growing Oncology API Market

| Editor: Marion Henig

Lonza announced plans to invest CHF 24 million to expand cytotoxic manufacturing capabilities in Visp, Switzerland. Cytotoxic APIs are commonly used in oncology therapeutics, which represent one of the fastest growing segments of the pharma and biotech industry.

Related Company

Lonza at its Visp Site, Switzerland (Picture: Lonza)
Lonza at its Visp Site, Switzerland (Picture: Lonza)

Basel, Switzerland – Lonza currently operates high potency GMP laboratory suites on gram-scale. The investment will add multi-kilogram scale cytotoxic production capacity which enables Lonza to offer clinical and commercial production of cytotoxics – all within one dedicated facility. With these enhanced fermentation and chemical capabilities, along with existing bioconjugation expertise, Lonza wants to comprehensively address its customers cytotoxic manufacturing challenges.

“With the anticipated expansion to be completed in the second quarter of 2012, Lonza Visp will offer a fully integrated end-to-end development and manufacturing solution for a wide-range of technologies, including highly active pharmaceutical ingredients (HAPIs), cytotoxics, peptides and antibody drug conjugates (ADCs)”, said Stefan Stoffel, Head of Lonza’s Chemical Manufacturing Business Unit.

The new facility will provide the necessary production lines to secure API supply and meet the regulatory requirements of the coming decade with strict focus on safe handling of compounds with low occupational exposure limits (OEL) to ensure employee and environmental safety.